STREPTOMYCIN SULFATE

Streptomycin Sulfate Overview

Streptomycin sulfate is a seminal aminoglycoside antibacterial agent derived from Streptomyces griseus, approved by the FDA in June 1998 in its standardized injectable formulation. It functions by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria, causing mRNA misreading, inhibition of protein synthesis, and rapid bactericidal cell death. Administered via deep intramuscular injection, streptomycin serves as a critical second-line agent in multidrug regimens for active tuberculosis and remains a drug of choice for severe zoonotic and systemic infections, including plague, tularemia, glanders, and enterococcal endocarditis. However, its broad antimicrobial utility is counterbalanced by significant risks of irreversible ototoxicity, nephrotoxicity, and neuromuscular blockade, requiring strict therapeutic monitoring and dosage individualization.

What Is Streptomycin Sulfate and How Does It Work?

Streptomycin sulfate is a water-soluble aminoglycoside antibiotic consisting of a streptidine ring linked to a streptobiosamine disaccharide. It exerts its therapeutic action by entering the bacterial cell wall via passive diffusion through outer membrane porins, followed by an energy-dependent active transport process across the inner cytoplasmic membrane that requires an aerobic microenvironment.

Once inside the cytoplasm, streptomycin binds firmly and specifically to the 16S rRNA component of the 30S ribosomal subunit. This binding distorts the A-site (aminoacyl site) of the ribosome, resulting in two distinct antibacterial mechanisms:

• Inhibition of Protein Initiation: It interferes with the initiation complex of protein synthesis, preventing the assembly of functional ribosomal units and halting overall peptide translation.
• Mistranslation of mRNA: It causes misreading of the genetic code on mRNA, causing incorrect amino acids to be incorporated into growing polypeptide chains. The accumulation of abnormal, non-functional, and toxic proteins damages the bacterial cytoplasmic membrane, increasing permeability and accelerating cellular lysis.

Because of this membrane-disrupting effect, streptomycin acts in a concentration-dependent bactericidal manner. It demonstrates significant activity against aerobic Gram-negative bacilli, Mycobacterium tuberculosis, and specific fastidious organisms. It exhibits no activity against anaerobic bacteria, as the intracellular transport of the drug relies strictly on oxidative phosphorylation pathways.

Is Streptomycin Sulfate FDA Approved?

Yes, streptomycin sulfate is fully FDA approved in the United States for deep intramuscular administration.

What Is Streptomycin Sulfate Used For?

• Tuberculosis: Indicated as a component of combination therapy for the treatment of active tuberculosis caused by susceptible strains of Mycobacterium tuberculosis. It is typically reserved for second-line or drug-resistant regimens due to parenteral administration requirements and toxicity profiles.
• Tularemia: Indicated as a drug of choice for the treatment of tularemia caused by Francisella tularensis.
• Plague: Indicated for the treatment of plague caused by Yersinia pestis.
• Bacterial Endocarditis: Indicated in combination with penicillin or ampicillin for the treatment of subacute or acute bacterial endocarditis caused by susceptible strains of Enterococcus species or Streptococcus viridans.
• Brucellosis and Glanders: Indicated in combination regimens (usually with tetracyclines) for the treatment of moderate to severe brucellosis (Brucella species) and glanders (Burkholderia mallei).
• Limitations of Use: Streptomycin should not be used as monotherapy for tuberculosis to prevent the rapid development of bacterial resistance.

Before Administering Streptomycin Sulfate: Contraindications & Precautions

Administering streptomycin requires meticulous baseline assessment due to the potential for severe, irreversible organ toxicities.

Who Should Not Receive Streptomycin Sulfate?

• Known Hypersensitivity: Strictly contraindicated in patients with a history of severe hypersensitivity reactions or toxic responses to streptomycin or any other aminoglycoside antibiotic (such as gentamicin, amikacin, or tobramycin), owing to cross-reactivity.

Important Warnings and Precautions

• Ototoxicity: Streptomycin causes severe, irreversible auditory and vestibular damage. Vestibular damage (manifesting as ataxia, vertigo, and dizziness) is particularly prominent with streptomycin compared to other aminoglycosides. Risk increases with high peak plasma levels, cumulative total doses, prolonged therapy, and pre-existing renal dysfunction.
• Nephrotoxicity: Aminoglycosides accumulate in the renal proximal tubular cells, predisposing patients to acute tubular necrosis and acute kidney injury. Baseline and periodic serum creatinine and blood urea nitrogen (BUN) monitoring are mandatory.
• Neuromuscular Blockade: Streptomycin can induce muscular weakness and acute respiratory paralysis through pre-synaptic blockade of acetylcholine release and post-synaptic receptor antagonism. Extreme caution is required in patients with neuromuscular disorders such as myasthenia gravis or Parkinson’s disease, or those receiving neuromuscular blocking agents.
• Fetal Toxicity: Streptomycin readily crosses the placenta and can cause permanent congenital bilateral sensorineural deafness in offspring when administered to a pregnant woman.

Streptomycin Sulfate Dosage & Administration

Streptomycin sulfate is formulated strictly for intramuscular (IM) injection following reconstitution with Sterile Water for Injection or 0.9 percent Sodium Chloride Injection. It must not be given intravenously.

Standard Clinical Dosing Guidelines

• Active Tuberculosis (Adults):

• Standard Dose: 1 gram (15 mg/kg) intramuscularly once daily in combination with other active antituberculosis agents.
• Reduced/Intermittent Schedule: In elderly patients or following initial therapeutic response, the dose is reduced to 1 gram 2 to 3 times weekly, up to a maximum cumulative dose (typically 60 to 90 grams over the full treatment course).
• Active Tuberculosis (Pediatrics):
• Standard Dose: 20 to 40 mg/kg of body weight (maximum 1 gram) intramuscularly once daily in combination therapy.
• Tularemia:
• Standard Dose: 1 to 2 grams daily in divided doses (every 6 to 12 hours) intramuscularly for 7 to 14 days, until the patient is afebrile for at least 5 to 7 days.
• Plague:
• Standard Dose: 2 grams daily in divided doses (every 6 to 12 hours) intramuscularly for 10 days.
• Enterococcal Endocarditis (Combination Therapy):
• Standard Dose: 1 gram intramuscularly twice daily for 2 weeks, followed by 500 mg twice daily for an additional 4 weeks in combination with penicillin.

Dosing Adjustments for Renal Impairment

• Because streptomycin is cleared almost entirely by glomerular filtration, dosing intervals must be extended or individual doses reduced based on estimated creatinine clearance and serum drug concentration monitoring to prevent toxic accumulation.

Streptomycin Sulfate Clinical Efficacy & Research

Discovered in 1943 by Selman Waksman’s research group, streptomycin was the first effective antibiotic treatment for tuberculosis, fundamentally altering modern infectious disease management. Landmark clinical trials conducted by the Medical Research Council in the late 1940s confirmed its life-saving efficacy in pulmonary and meningeal tuberculosis. Over decades of clinical research, protocol refinements established that integrating streptomycin into multidrug regimens prevents single-drug resistance selection while rapidly sterilizing sputum cultures. Furthermore, clinical experience continues to confirm its position as a primary therapeutic agent for life-threatening zoonotic outbreaks, such as pneumonic plague and tularemia.

Streptomycin Sulfate Side Effects & Safety Profile

BOXED WARNING: RISK OF OTOTOXICITY, NEPHROTOXICITY, AND NEUROMUSCULAR BLOCKADE

• Ototoxicity: Streptomycin can cause permanent damage to the eighth cranial nerve (vestibulocochlear nerve), resulting in irreversible hearing loss, vertigo, and loss of balance.
• Nephrotoxicity: Aminoglycosides possess nephrotoxic potential; renal function must be closely monitored.
• Neuromuscular Blockade: Can cause neuromuscular blockade resulting in muscle weakness and respiratory paralysis, particularly when co-administered with anesthetics or neuromuscular blockers.
• Fetal Toxicity: May cause fetal harm (including permanent congenital deafness) when administered to pregnant women.

Common Adverse Reactions

• Vestibular Disturbances: Vertigo, dizziness, loss of balance, and gait ataxia.
• Local Injection Reactions: Pain, tenderness, induration, and sterile abscesses at the intramuscular injection site.
• Neurological Sensations: Circumoral paresthesia (tingling around the mouth and face), numbness, and peripheral neuropathy.
• Systemic Reactions: Fever, skin rash, nausea, and vomiting.

Serious Adverse Events

• Irreversible Hearing Loss: Progressive high-frequency sensorineural hearing loss or total deafness.
• Acute Kidney Injury: Marked elevations in serum creatinine, oliguria, proteinuria, and tubular necrosis.
• Respiratory Paralysis: Acute respiratory failure secondary to neuromuscular blockade.
• Anaphylaxis: Severe hypersensitivity reactions, angioedema, and drug fever.

Streptomycin Sulfate Drug Interactions & What to Avoid

Streptomycin requires extreme caution when combined with agents sharing overlapping toxicities or those altering renal clearance.

Critical Drug Interactions

• Nephrotoxic and Ototoxic Agents: Co-administration with other potentially ototoxic or nephrotoxic drugs such as amphotericin B, cisplatin, vancomycin, capreomycin, polymyxin B, colistin, or other aminoglycosides severely increases the risk of renal failure and permanent cranial nerve damage.
• Loop Diuretics: Concurrent use of potent loop diuretics (e.g., furosemide, ethacrynic acid, bumetanide) enhances aminoglycoside ototoxicity by altering electrolyte concentrations in the inner ear fluid and transiently elevating serum antibiotic levels.
• Neuromuscular Blocking Agents: Concomitant use with muscle relaxants (e.g., succinylcholine, tubocurarine, vecuronium) or general anesthetics potentiates neuromuscular blockade, risking sudden respiratory depression and prolonged apnea.
• Cephalosporins: Concurrent use of certain high-dose cephalosporins may increase the risk of nephrotoxicity.

Streptomycin Sulfate: Missed Dose, Overdose & Storage

Missed Dose Guidelines

Because streptomycin is administered by healthcare professionals in a clinical or hospital setting, missed doses are uncommon. If an intramuscular dose is delayed, it should be administered as soon as possible. The remaining schedule should then be adjusted to maintain consistent therapeutic intervals. Clinicians should never administer a double dose to compensate for a missed injection.

Overdose Protocols

Streptomycin overdose leads to exaggerated manifestations of its toxic profile, including profound renal failure, acute respiratory muscle paralysis, vestibular collapse, and deafness. Emergency management includes immediate cessation of the drug and supportive airway maintenance. If neuromuscular blockade occurs, calcium salts (such as calcium gluconate) or anticholinesterase agents (such as neostigmine) may be administered intravenously to reverse muscle paralysis. Both hemodialysis and peritoneal dialysis effectively remove streptomycin from systemic circulation, which is vital in patients with compromised renal function.

Storage Instructions

Store intact vials of lyophilized streptomycin powder at controlled room temperature between 20 and 25 degrees Celsius (68 and 77 degrees Fahrenheit). Protect the powder from light and excessive moisture. Once reconstituted with sterile water for injection, the solution maintains chemical stability for 24 hours at room temperature and up to 14 days when refrigerated between 2 and 8 degrees Celsius.

Streptomycin Sulfate Patient Management & Monitoring

Safe therapy requires mandatory baseline laboratory and audiometric evaluations alongside continuous clinical surveillance.

Clinical Assessment Before Administration

• Baseline Audiometry: Perform baseline audiometric and vestibular function testing prior to initiating extended therapy to detect pre-existing hearing loss.
• Baseline Renal Function: Obtain baseline serum creatinine, blood urea nitrogen (BUN), and urinalysis.
• Pregnancy Screening: Perform pregnancy testing in female patients of childbearing potential due to fetal ototoxicity risks.
• Neuromuscular Screening: Screen for pre-existing neuromuscular disease such as myasthenia gravis.

Monitoring During Administration

• Auditory and Vestibular Surveillance: Evaluate the patient regularly for complaints of tinnitus, roaring in the ears, fullness in the auditory canal, dizziness, or unsteady gait. Perform serial audiograms during prolonged therapy.
• Renal Function Monitoring: Measure serum creatinine and BUN bi-weekly or weekly throughout the treatment course.
• Therapeutic Drug Monitoring (TDM): Measure peak and trough serum streptomycin concentrations to ensure therapeutic efficacy while minimizing toxic accumulation. Peak levels should generally be maintained between 25 and 35 mcg/mL, while trough levels should remain below 5 mcg/mL.
• Injection Site Inspection: Rotate intramuscular injection sites daily (typically alternating deep gluteal muscles) to prevent local muscle necrosis and induration.

Frequently Asked Questions

References

• U.S. Food and Drug Administration Label Information for Streptomycin Sulfate for Injection.
• World Health Organization (WHO) Operational Handbook on Tuberculosis: Module 4: Treatment – Drug-Susceptible Tuberculosis Treatment.
• Centers for Disease Control and Prevention (CDC) Prevention and Treatment Guidelines for Tularemia and Plague.

Legal Disclaimer

This educational document is intended for informational purposes only and does not substitute for formal medical advice, clinical diagnosis, or specialized treatment protocols. Always consult a qualified infectious disease physician, pulmonologist, or clinical pharmacist with specific questions regarding tuberculosis regimens, aminoglycoside therapeutic drug monitoring, or ototoxicity management.